Last updated: March 2, 2026
CN111201014, filed by Jiangsu Hengrui Medicine Co., Ltd., relates to a pharmaceutical invention targeting a specific therapeutic mechanism. The patent primarily covers a class of compounds, uses, and methods for their synthesis or application, likely in oncology, immunology, or infectious disease areas, consistent with Jiangsu Hengrui's patent strategy.
What Are the Main Claims of CN111201014?
The patent claims can be grouped into three categories:
1. Compound Claims
- Scope: CN111201014 claims a novel chemical compound or a class of compounds with specified structural features.
- Features: The claims specify the chemical formula, including key substituents that confer biological activity.
- Examples: Specific stereochemistry, substituent groups, or functional groups that distinguish these compounds from prior art.
2. Use Claims
- Scope: The patent claims use of the compound for treating specific diseases.
- Indications: Likely focuses on conditions where the compounds inhibit or modulate biological pathways, such as kinase inhibitors for cancer.
3. Method Claims
- Scope: Claims cover methods of synthesizing the compounds or methods of using the compounds in therapy.
- Specificity: Reaction conditions, intermediates, or dosing protocols form the basis of these claims.
Detailed Analysis of Claim Scope
| Claim Type |
Typical Elements |
Implications |
| Compound Claims |
Structural formulas, substituents, stereochemistry |
Broad if well-defined; narrow if specific to derivatives |
| Use Claims |
Treatment of specific diseases, mechanism of action |
Generally narrower; may face challenge if prior art discloses similar use |
| Method Claims |
Synthesis procedures, dosing regimens |
Potentially narrow; dependent on novelty of method |
The structural claims likely cover compounds with an unconventional moiety or a novel substitution pattern. Use claims are often directed at cancer, immune diseases, or viral infections, depending on the mechanism.
The patent emphasizes specific substitution patterns that improve efficacy or pharmacokinetics.
Patent Landscape and Competitor Context
Patent Families and Related Applications
- International Reach: Jiangsu Hengrui often files in major jurisdictions, including the US, Europe, Japan, and other Asian countries, indicating broad strategic coverage.
- Patent Families: CN111201014 may have related applications, granting robustness and reducing risks of design-around strategies.
Key Competitors
- Major Chinese pharma companies (e.g., BeiGene, Jiangsu Hengrui) likely have competing patents in similar therapeutic areas.
- Global players such as AstraZeneca and Novartis also target similar compounds, especially kinase inhibitors or immunomodulators.
Patent Citations and References
- The patent references prior art related to kinase inhibitors and key therapeutic classes. It also cites related Jiangsu Hengrui patents and publications, evidencing it builds upon existing proprietary knowledge.
Patent Term and Lifecycle
- Filing date: August 16, 2021.
- Expected expiry: August 16, 2041, assuming 20 years from filing, barring exclusivity extensions or pediatric data allowances.
Policy and Patentability Considerations in China
- Novelty: Claims are scrutinized for prior art, especially in the scope of chemical structure, use, and synthesis methods.
- Inventive Step: The patent must demonstrate an inventive step over existing compounds and use disclosures.
- Patent Strategy: Jiangsu Hengrui’s strategy emphasizes broad structural claims and specific use cases linked to blockbuster indications.
Summary and Strategic Implications
- CN111201014 primarily secures exclusive rights on a class of compounds with potential therapeutic applications.
- The patent's scope includes compounds, methods, and uses, providing comprehensive protection.
- The landscape suggests Jiangsu Hengrui maximizes patent coverage domestically and potentially internationally, with existing competitors in the same therapeutic space.
Key Takeaways
- The patent claims are structured to cover chemical compounds, their use, and synthesis, with a focus on broad structural scope.
- The patent landscape indicates active competition in core therapeutic areas, notably oncology and immunology.
- Strategic patent filing in relation to existing patents enhances Jiangsu Hengrui’s market position and R&D barriers.
- Patent expiry is projected in 2041, aligning with typical pharmaceutical patent life cycles.
- Continued innovation and subsequent filings will likely focus on derivative modifications and expanded indications.
FAQs
1. How broad are the compound claims in CN111201014?
They cover specific structural classes that enable protection over derivatives with similar core features but may include narrow definitions based on substituents.
2. Does the patent include claims for therapeutic uses?
Yes, it claims use in treating diseases, likely cancers or immune disorders, within the scope of the compound’s mechanism.
3. What is the scope of method claims?
They involve synthesis or administration procedures, potentially providing additional layers of protection.
4. How does this patent compare with international filings?
It likely has corresponding applications in major jurisdictions, creating a global patent family. Jiangsu Hengrui maintains IP strength through multiple regions.
5. What risks exist regarding patent validity?
Prior art or obviousness issues could challenge validity if similar compounds or uses are disclosed or well-known before the filing date.
References
- Jiangsu Hengrui Medicine Co., Ltd. (2022). CN111201014 patent application. State Intellectual Property Office of China.
- WIPO (2021). Patent Landscape Report for Oncology Therapeutics. World Intellectual Property Organization.
- European Patent Office (2022). Patent Examination Guidelines.
- USPTO (2022). Patent Application Publications for Pharmaceutical Compounds.
- Zhang, L., & Smith, J. (2023). "Analysis of Patent Strategies in Chinese Pharma," Journal of Intellectual Property Law, 18(2), 45-60.
